Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CASI Launches Pralatrexate in China for R/R Peripheral T-cell Lymphoma

publication date: Feb 16, 2024

CASI Pharma, a Maryland-Beijing company, dosed the first patient with Folotyn® (Pralatrexate Injection), a dihydrofolate reductase inhibitor aimed at relapsed or refractory peripheral T-cell lymphoma (PTCL). In August 2023, CASI acquired China distribution rights to the drug, a long-time therapy for the indication in the west, from Mundipharma International. The drug was approved for China use as a first-line therapy in 2020 for PTCL. CASI acquires and develops therapies for hematological cancers in China. The company’s website lists five candidates in current development. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital